The majority of medical devices are cleared for marketing in the U.S. by the FDA under the 510(k) process. The FDA holds companies responsible for filing new 510(k)s when new products are to be marketed in the U.S., or when existing products and/or their Indications for Use are changed. What are the 21 mandatory elements? How is Substantial Equivalence determined, proved, documented? What about IDE's, De Novo's or PMAs? And how to initiate dialog with theAgency under the Q-Submission program.. What should be included, and what should only be referenced. What new concerns need to be addressed now? How can companies make such determinations? What approaches are required for product changes; for process changes? What about software "in-" or "as-product"? How does ISO 14971 Risk Management fit into the submission documentation process?
Why Should You Attend:
The U.S. FDA mandates that the traditional 510(k) submission address 21 basic requirements. The "Special" and "Abbreviated" 510(k)s must also address them, but in different ways. In addition, the FDA Task Force has identified several problem areas with the existing medical device 510(k) process, leading to the growing push by the Agency to strengthen the 510(k) process. What can companies do in proactively addressing these issues, to "put the reviewer's mind at ease" when reviewing a 510(k)? How can we use a similar format and rationale for IDE's, De Novo's, and even PMAs. Use of the Q-Sub to initiate dialog with the Agency.
Areas Covered in the Webinar:
Who Will Benefit:
Expectations for meaningful, results driven device submissions and documented product development activities are increasing among the U.S. FDA, as well as similar expectations by regulatory agencies world wide. Growing high-profile field problems indicate that design control and it’s effect on new/changed product and the submission review process is not as formal and rigorous as the FDA expects. How can a company maximize the data to prove compliance to the 21 FDA-defined requirements for a valid submission. For most companies, proactively addressing these concerns, spoken or unspoken, are not rocket-science. Proactive implementation in current device submissions can minimize wasted resources, assist the FDA reviewer to clear the submission, speed the entire process, and minimize the chance of unnecessary delays in the FDA's decision.
John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 41 years experience in U.S. FDA-regulated industries, 27 years as head of his own consulting company. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has ptublished numerous articles in peer reviewed journals, 5 chapters in the RAPS textbook on validation, conducted workshops and webinars worldwide on CGMP subjects. John is a graduate of UCLA.
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
PAYMENT METHOD: 100% Secure Transaction